350% Gainer Highlights 5 of Today’s Hottest Stocks

Next up is Celator Pharmaceuticals Inc (NASDAQ:CPXX), with shares of the biopharmaceutical company being up by an astounding 360% after the announcement of surprisingly positive results from a Phase 3 trial for its lead drug VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351), for the treatment of patients with high-risk (secondary) acute myeloid leukemia (AML). The patients who were receiving VYXEOS showed an improvement in overall survival (OS) compared with the standard-of-care regimen of cytarabine and daunorubicin known as 7+3. For this group, patients experienced an average OS of 9.56 months versus 5.95 months. The data will be presented at the American Society of Clinical Oncology 2016 Annual Meeting in Chicago in mid-year. As a consequence, analysts at Roth Capital are more bullish on the company today, as they raised their price target on it to $22 per share from $18 per share.

Celator Pharmaceuticals Inc (NASDAQ:CPXX) was not overly popular among the investors in our system, as a total of three investors reported long positions as of the end of December, amassing 3.0% of the company’s outstanding stock. First Eagle Investment Management was one of those three, with a holding of 612,600 shares.

Next on our list of gainers is Childrens Place Inc (NASDAQ:PLCE), whose shares have surged by 5% after the company reported fourth-quarter EPS of $1.19, beating analysts’ estimates by $0.08 per share. The company’s revenue of $498.54 million meanwhile was in-line with the Street’s estimates. In the same period of the prior year, the largest pure-play children’s specialty apparel retailer posted a profit of $0.94 per share on $479.2 million in revenue. For fiscal year 2016, Childrens Place expects that adjusted net income per diluted share will be in the range of $4.00 to $4.10, including between $1.00 and $1.06 in the first quarter of 2016.

Our data shows hedge funds were growing more bullish on Childrens Place Inc (NASDAQ:PLCE), with 17 of the smart money investors in our database reporting stakes in the company as of the end of the fourth quarter, up from 12 funds long the stock on September 30. Chuck Royce’s Royce & Associates owned a stake of 1.84 million shares at the end of December.

Last but not least, HD Supply Holdings Inc (NASDAQ:HDS) has jumped by 5% after it reported fourth-quarter EPS of $0.27 on revenue of $1.65 billion. HD Supply’s revenue beat expectations by $20 million and amounted to 7.1% year-over-year growth. Moreover, the largest industrial distributor’s operating income improved by 8% to $130 million, while adjusted EBITDA increased by 8% to $167 million during the period.

45 funds were long HD Supply Holdings at the end of the fourth quarter, down from 54 funds long the stock at the close of the third quarter. John Griffin‘s Blue Ridge Capital held 8.28 million HDS shares on December 31.

Disclosure: None